Clinical Trial Update: PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

View source ↗

Summary

PROPEL is a prospective observational patient registry sponsored by Inozyme Pharma to evaluate ENPP1 deficiency and ABCC6 deficiency. The registry is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abcc6 Deficiency
• Enpp1 Deficiency

Snippet

Sponsor: Inozyme Pharma | Conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency | Status: RECRUITING